BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23186986)

  • 1. Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study.
    Gabelle A; Dumurgier J; Vercruysse O; Paquet C; Bombois S; Laplanche JL; Peoc'h K; Schraen S; Buée L; Pasquier F; Hugon J; Touchon J; Lehmann S
    J Alzheimers Dis; 2013; 34(1):297-305. PubMed ID: 23186986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
    Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
    J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting.
    Dumurgier J; Vercruysse O; Paquet C; Bombois S; Chaulet C; Laplanche JL; Peoc'h K; Schraen S; Pasquier F; Touchon J; Hugon J; Lehmann S; Gabelle A
    Alzheimers Dement; 2013 Jul; 9(4):406-13. PubMed ID: 23141384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
    Engelborghs S
    Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
    Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
    J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exacerbated CSF abnormalities in younger patients with Alzheimer's disease.
    Dumurgier J; Gabelle A; Vercruysse O; Bombois S; Laplanche JL; Peoc'h K; Schraen S; Sablonnière B; Pasquier F; Touchon J; Lehmann S; Hugon J; Paquet C
    Neurobiol Dis; 2013 Jun; 54():486-91. PubMed ID: 23416172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers.
    Spies PE; Claassen JA; Peer PG; Blankenstein MA; Teunissen CE; Scheltens P; van der Flier WM; Olde Rikkert MG; Verbeek MM
    Alzheimers Dement; 2013 May; 9(3):262-8. PubMed ID: 23123231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
    Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Added diagnostic value of CSF biomarkers in differential dementia diagnosis.
    Le Bastard N; Martin JJ; Vanmechelen E; Vanderstichele H; De Deyn PP; Engelborghs S
    Neurobiol Aging; 2010 Nov; 31(11):1867-76. PubMed ID: 19150153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic impact of CSF biomarkers in a local hospital memory clinic.
    Kester MI; Boelaarts L; Bouwman FH; Vogels RL; Groot ER; van Elk EJ; Blankenstein MA; van der Flier WM; Scheltens P
    Dement Geriatr Cogn Disord; 2010; 29(6):491-7. PubMed ID: 20523047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls.
    Struyfs H; Molinuevo JL; Martin JJ; De Deyn PP; Engelborghs S
    J Alzheimers Dis; 2014; 41(3):903-9. PubMed ID: 24705548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia.
    Engelborghs S; Le Bastard N
    J Neurol Sci; 2012 Nov; 322(1-2):197-9. PubMed ID: 22947896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid biomarkers in Progranulin mutations carriers.
    Carecchio M; Fenoglio C; Cortini F; Comi C; Benussi L; Ghidoni R; Borroni B; De Riz M; Serpente M; Cantoni C; Franceschi M; Albertini V; Monaco F; Rainero I; Binetti G; Padovani A; Bresolin N; Scarpini E; Galimberti D
    J Alzheimers Dis; 2011; 27(4):781-90. PubMed ID: 21891865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels.
    Slaets S; Le Bastard N; Martin JJ; Sleegers K; Van Broeckhoven C; De Deyn PP; Engelborghs S
    J Alzheimers Dis; 2013; 36(4):759-67. PubMed ID: 23666174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
    Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K
    J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical AD predicts decline in memory and executive functions in subjective complaints.
    van Harten AC; Smits LL; Teunissen CE; Visser PJ; Koene T; Blankenstein MA; Scheltens P; van der Flier WM
    Neurology; 2013 Oct; 81(16):1409-16. PubMed ID: 24049134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A new approach to the Alzheimer's disease diagnosis with biomarkers: description of the AD-CSF-Index].
    Molinuevo JL; Gispert JD; Pujol J; Rojas S; Lladó A; Balasa M; Antonell A; Sánchez-Valle R; Rami L
    Rev Neurol; 2012 May; 54(9):513-22. PubMed ID: 22532214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The AD-CSF-index discriminates Alzheimer's disease patients from healthy controls: a validation study.
    Molinuevo JL; Gispert JD; Dubois B; Heneka MT; Lleo A; Engelborghs S; Pujol J; de Souza LC; Alcolea D; Jessen F; Sarazin M; Lamari F; Balasa M; Antonell A; Rami L
    J Alzheimers Dis; 2013; 36(1):67-77. PubMed ID: 23524657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.